Biotech

Startups News

Biotech Startups Essentials publishes only the best Biotech news and links, carefully hand-picked and curated by top biotech experts.

Top news of the week: 21.06.2022.

Biotechnology
Drug
Finance
Initial public offering
Dot-com bubble
New York City

@Forbes shared
On Jun 16, 2022
Intellia Therapeutics has figured out how to alter disease-causing genes inside patients, but before any breakthrough treatments come, it must first cure itself of its legal and financial ills. https://t.co/4kixjnlzkp
Open
06:34am EDT

06:34am EDT

John Leonard built Intellia Therapeutics with Jennifer Doudna, the Nobel Prize-winning scientist who pioneered gene editing technology. Intellia has figured out how to alter disease-causing ...

@BentheFidler shared
On Jun 15, 2022
With #biotech in retreat, Third Rock raises $1B for life sciences investing https://t.co/TUsF0V1uqa by @realJacobBell #startups @ThirdRockV
Open
With biotech in retreat, Third Rock raises $1B for life sciences investing

With biotech in retreat, Third Rock raises $1B for life sciences investing

The fund, Third Rock’s sixth, comes amid a significant downturn in the biotech stock market, which has raised questions about the viability of young drug startups.

@ScottKirsner shared
On Jun 15, 2022
.@ThirdRockV raises $1.1 billion for its largest fund yet https://t.co/XsFkMj2jmb via @BostonGlobe & @RLCscienceboss #biotech #vc
Open
Third Rock raises $1.1 billion for its largest fund yet

Third Rock raises $1.1 billion for its largest fund yet

The Boston venture capital firm plans to use the money to launch more biotechs, despite the sector’s recent downturn.

@adamfeuerstein shared
On Jun 15, 2022
Third Rock Ventures plots next chapter after raising $1.1 billion fund https://t.co/1pYy0pybyl via @ADeAngelis_bio
Open
Third Rock Ventures plots next chapter after raising $1.1 billion fund

Third Rock Ventures plots next chapter after raising $1.1 billion fund

Third Rock Venture partners Abbie Celniker and Reid Huber spoke with STAT about their plans for investing their sixth and largest fund. The lion's share of the $1.1 billion they raised will ...

@big4bio shared
On Jun 16, 2022
RT @LongfellowREP: Today, @biolabs announced their new laboratory location at @LongfellowREP BioVista in San Diego! Full release and details: https://t.co/uqQcneOyB1 https://t.co/v72iKbVu5F
Open
BioLabs Announces New Laboratory Location at Longfellow’s BioVista

BioLabs Announces New Laboratory Location at Longfellow’s BioVista

BioLabs announces new laboratory location at Longfellow’s BioVista San Diego, CA (June 15, 2022) – BioInnovation Labs, “BioLabs”, the leading developer and operator of life …

@GENbio shared
On Jun 16, 2022
Thermo’s New Single-Use Site in Utah Thermo built its new Ogden, UT-based facility to manufacture bioprocess container systems that can be customized. Learn more: https://t.co/ll8ZxuzKf1 https://t.co/tbdTcSNw4N
Open
Thermo’s New Single-Use Site in Utah

Thermo’s New Single-Use Site in Utah

Thermo built its new Ogden, UT-based facility to manufacture bioprocess container systems that can be customized. These systems can be used in many manufacturing steps, such as processing, ...

@John_LaMattina shared
On Jun 20, 2022
Pharma Critic Wrongly Minimizes Industry’s Covid-19 Vaccine Efforts https://t.co/mF4KlzjXQg via @forbes
Open
Pharma Critic Wrongly Minimizes Industry’s Covid-19 Vaccine Efforts

Pharma Critic Wrongly Minimizes Industry’s Covid-19 Vaccine Efforts

Pfizer, which has produced the majority of Covid-19 vaccines with roughly seven billion doses to date, took no money from Operation Warp Speed (OWS) to discover, produce or distribute its ...

@John_LaMattina shared
On Jun 18, 2022
RT @kenkaitin: The Days of Big Pharma Are Over. What the Era of Big Biotech Means for Investors. https://t.co/OO8yLyps6z Excellent @barronsonline story by @joshnathankazis on pharma sector priorities. Scientific opportunity & favorable competitive landscape drive R&D. Not all patients benefit
Open
The Days of Big Pharma Are Over. What the Era of Big Biotech Means for Investors.

The Days of Big Pharma Are Over. What the Era of Big Biotech Means for Investors.

When GSK spins off its consumer health division in July, it will become one of the last drug conglomerates to shed its sideline businesses to focus on...